CORV - Cardiome Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.68
-0.22 (-5.64%)
At close: 4:00PM EDT

3.37 -0.31 (-8.42%)
After hours: 6:08PM EDT

Stock chart is not supported by your current browser
Previous Close3.90
Open3.80
Bid3.35 x 1100
Ask4.18 x 800
Day's Range3.62 - 3.80
52 Week Range1.31 - 4.20
Volume116,829
Avg. Volume296,501
Market Cap128.739M
Beta-0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.55
Trade prices are not sourced from all markets
  • What You Must Know About Correvio Pharma Corp’s (TSE:CORV) Financial Strength
    Simply Wall St.5 days ago

    What You Must Know About Correvio Pharma Corp’s (TSE:CORV) Financial Strength

    Investors are always looking for growth in small-cap stocks like Correvio Pharma Corp (TSX:CORV), with a market cap of CA$105.66M. However, an important fact which most ignore is: how financiallyRead More...

  • ACCESSWIRE7 days ago

    Today’s Research Reports on Stocks to Watch: CRISPR Therapeutics and Cardiome Pharma

    NEW YORK, NY / ACCESSWIRE / June 12, 2018 / CRISPR technology stocks saw losses in Monday trading, which included CRISPT Therapeutics, after a STAT report revealed that using CRISPR/Cas9 technology with a cell's genome may cause cancer. Shares of Cardiome Pharma saw gains on the other hand after revealing encouraging news about the FDA responding regarding its regulatory path forward in the US for its BRINAVESS drug. CRISPR Therapeutics AG shares closed down 12.59% on about 8.2 million shares traded on Monday.

  • PR Newswire8 days ago

    Correvio Provides U.S. Regulatory Update for BRINAVESS

    VANCOUVER, June 11, 2018 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) regarding the regulatory path forward in the US for BRINAVESS® (vernakalant hydrochloride, IV), Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF). In its written reply, the FDA informed Correvio that it would be permissible to resubmit the BRINAVESS New Drug Application (NDA) and agreed that the Company may schedule a Pre-NDA meeting. Correvio currently expects that the Pre-NDA meeting with the FDA will take place in the fourth quarter of 2018.

  • CNW Group8 days ago

    Correvio Provides U.S. Regulatory Update for BRINAVESS

    VANCOUVER , June 11, 2018 /CNW/ - Correvio Pharma Corp. (CORV) (CORV.TO), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) regarding the regulatory path forward in the US for BRINAVESS® (vernakalant hydrochloride, IV), Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF). In its written reply, the FDA informed Correvio that it would be permissible to resubmit the BRINAVESS New Drug Application (NDA) and agreed that the Company may schedule a Pre-NDA meeting. Correvio currently expects that the Pre-NDA meeting with the FDA will take place in the fourth quarter of 2018.

  • CNW Group13 days ago

    Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS

    Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS

  • Where Correvio Pharma Corp’s (TSE:CORV) Earnings Growth Stands Against Its Industry
    Simply Wall St.19 days ago

    Where Correvio Pharma Corp’s (TSE:CORV) Earnings Growth Stands Against Its Industry

    Examining Correvio Pharma Corp’s (TSX:CORV) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...